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Summary
Background Low circulating concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, are 
associated with an increased risk of type 2 diabetes, but whether this association is causal remains unclear. We aimed 
to estimate the unconfounded, causal association between 25(OH)D concentration and risk of type 2 diabetes using a 
mendelian randomisation approach.
Methods Using several data sources from populations of European descent, including type 2 diabetes cases and non-
cases, we did a mendelian randomisation analysis using single nucleotide polymorphisms (SNPs) within or near four 
genes related to 25(OH)D synthesis and metabolism: DHCR7 (related to vitamin D synthesis), CYP2R1 (hepatic 
25-hydroxylation), DBP (also known as GC; transport), and CYP24A1 (catabolism). We assessed each SNP for an 
association with circulating 25(OH)D concentration (5449 non-cases; two studies), risk of type 2 diabetes (28 144 cases, 
76 344 non-cases; ﬁ ve studies), and glycaemic traits (concentrations of fasting glucose, 2-h glucose, fasting insulin, 
and HbA1c; 46 368 non-cases; study consortium). We combined these associations in a likelihood-based mendelian 
randomisation analysis to estimate the causal association of 25(OH)D concentration with type 2 diabetes and the 
glycaemic traits, and compared them with that from a meta-analysis of data from observational studies (8492 cases, 
89 698 non-cases; 22 studies) that assessed the association between 25(OH)D concentration and type 2 diabetes.
Findings All four SNPs were associated with 25(OH)D concentrations (p<10–⁶). The mendelian randomisation-derived 
unconfounded odds ratio for type 2 diabetes was 1·01 (95% CI 0·75–1·36; p=0·94) per 25·0 nmol/L (1 SD) lower 
25(OH)D concentration. The corresponding (potentially confounded) relative risk from the meta-analysis of data 
from observational studies was 1·21 (1·16–1·27; p=7·3 × 10–¹⁹). The mendelian randomisation-derived estimates for 
glycaemic traits were not signiﬁ cant (p>0·25).
Interpretation The association between 25(OH)D concentration and type 2 diabetes is unlikely to be causal. Eﬀ orts to 
increase 25(OH)D concentrations might not reduce the risk of type 2 diabetes as would be expected on the basis of 
observational evidence. These ﬁ ndings warrant further investigations to identify causal factors that might increase 
25(OH)D concentration and also reduce the risk of type 2 diabetes.
Funding UK Medical Research Council Epidemiology Unit and European Union Sixth Framework Programme.
Copyright © Ye et al. Open Access article distributed under the terms of CC BY. 
Introduction
Vitamin D is a steroid hormone that has a crucial role in 
the modulation of bone homeostasis. It has been described 
as a wonder vitamin because of its possible beneﬁ ts 
related to diverse health outcomes including bone disease, 
coronary heart disease, and type 2 diabetes.1–3 
25-hydroxyvitamin D (25[OH]D) is a circulating meta-
bolite used as a clinical indicator of vitamin D status. 
Results from prospective epidemiological studies have 
shown that low circulating 25(OH)D concentrations are 
associated with an increased risk of developing type 2 
diabetes.3,4 However, whether or not this association is 
causal is unknown;3 it might be the result of residual 
confounding, which is plausible in observational studies 
of incident type 2 diabetes. Measurements of confounders 
(eg, physical activity) are susceptible to errors and are not 
adequately controlled for in epidemiological analyses.5 
Although results from clinical trials6,7 have shown no 
eﬀ ect of vitamin D supplementation on the incidence of 
type 2 diabetes, these ﬁ ndings require cautious 
interpretation because of issues with doses, combination 
treatment with calcium, compliance, and generalisability.3
Studies of genetic variants (single nucleotide 
polymorphisms, SNPs) that speciﬁ cally aﬀ ect 25(OH)D 
concentration can provide another route to draw causal 
inference. Investigators of a genome-wide association 
study8 identiﬁ ed SNPs within or near four genes 
signiﬁ cantly related to 25(OH)D concentrations: DHCR7 
(encoding 7-dehydrocholesterol reductase; involved in 
25[OH]D synthesis in the skin) and CYP2R1 (encoding 
cytochrome P450, family 2, subfamily R, polypeptide 1; 
involved in hepatic 25-hydroxylation), both representing 
25(OH)D synthesis; and DBP (also known as GC; 
encoding vitamin D-binding protein; involved in 25[OH]
D transport) and CYP24A1; (encoding cytochrome P450, 
family 24, subfamily A, polypeptide 1; involved in 25[OH]
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D catabolism), both representing vitamin D metabolism. 
SNPs within or near these genes have been investigated 
as instruments to predict 25(OH)D concentrations 
independent of potential confounders and to study causal 
associations of 25(OH)D concentrations with health 
outcomes.2,9–12 Using a mendelian randomisation 
approach, investigators of previous studies have 
examined causal associations of 25(OH)D with risk of 
type 2 diabetes, but these studies were unable to conﬁ rm 
or refute causality because of small sample sizes, few 
included SNPs, or the absence of validation (ie, through 
assessment of intermediate risk factors including 
glycaemic traits).9–11 Larger studies are needed to assess 
more precisely the potential causal association between 
25(OH)D concentrations and risk of type 2 diabetes. If 
causality does exist, interventions such as sunlight 
exposure or increased vitamin D intake (diet or 
supplementation) could provide a simple, inexpensive, 
and safe prevention strategy for type 2 diabetes. 
Resolution of this uncertainty is therefore important.
In this study, our main aim was to estimate the 
unconfounded, causal association between 25(OH)D 
concentrations and risk of type 2 diabetes using a 
mendelian randomisation approach, combining data 
from several studies. We also examined causal 
associations between 25(OH)D concentrations and 
glycaemic traits as secondary outcomes.
Methods
Study design
Based on the genome-wide associations previously 
identiﬁ ed,8 we used four SNPs as primary genetic 
instruments: rs12785878 near DHCR7, rs10741657 near 
CYP2R1, rs4588 of DBP, and rs17217119 near CYP24A1. 
Mendelian randomisation analysis requires genetic 
variants to be related to a main exposure, but not to 
potential confounders.13,14 Thus, we ﬁ rst assessed the 
association of each of the four SNPs with 25(OH)D 
concentrations and other baseline factors (eg, BMI, blood 
pressure, and physical activity). Second, we examined the 
association between each SNP and risk of type 2 diabetes. 
Third, we combined these ﬁ ndings to estimate the 
unconfounded, causal association between 25(OH)D 
concentrations and risk of type 2 diabetes by mendelian 
randomisation analysis. Fourth, we also did mendelian 
randomisation analysis to estimate the unconfounded, 
causal association between 25(OH)D concentration and 
four glycaemic traits: concentrations of fasting glucose, 
2-h glucose (during a standard oral glucose tolerance 
test), fasting insulin, and HbA1c. Finally, for comparison 
with the mendelian randomisation-based estimates, we 
meta-analysed data from prospective observational 
studies that assessed the association between 25(OH)D 
concentrations and risk of type 2 diabetes.
Data sources for mendelian randomisation analysis
We used several data sources from populations of European 
descent (ﬁ gure 1, appendix pp 2–5).15 We derived 
associations of SNPs with 25(OH)D concentrations using 
data from the Ely16 (n=684) and EPIC-Norfolk4 (n=4765) 
studies, assessing randomly selected adults with SNPs and 
25(OH)D data available. 56 participants from the Ely study 
and 2020 from the EPIC-Norfolk study were excluded 
because data were not available. Associations of SNPs with 
risk of type 2 diabetes were based on 28 144 cases of 
type 2 diabetes and 76 344 non-cases from a case-cohort 
study (EPIC-InterAct)17 and four case-control studies 
(the DIAGRAM consortium,18 ADDITION-Ely,19,20 Norfolk 
Diabetes,15 and Cambridgeshire15). Among participants 
assessed for SNPs, up to 4·5% were excluded because of 
missing genetic information. Some datasets included some 
overlap of study participants, but we ensured that these 
were not double-counted (appendix pp 2-4).15 Such overlap 
was present between the ADDITION-Ely and Ely studies, 
and between the Norfolk Diabetes, EPIC-Norfolk, and 
EPIC-InterAct studies. Apart from a few studies in 
DIAGRAM, all studies ascertained type 2 diabetes cases 
through biochemical testing (concentrations of fasting 
glucose, 2-h glucose, or HbA1c), diabetes registries, or 
medical records (appendix p 3). For associations between 
SNPs and glycaemic traits, we assessed summary data 
from 46 368 Europeans without diabetes in the Meta-
Analyses of Glucose and Insulin-related traits Consortium 
(MAGIC)21. Ethical approval was obtained for all studies 
included in this analysis.
Measurement of 25(OH)D concentration and SNPs
Circulating concentrations of 25(OH)D in the Ely16 and 
EPIC-Norfolk4 studies were measured as previously 
reported. The four SNPs included in our analysis (or 
SNPs in linkage disequilibrium, with r²>0·99) were 
previously identiﬁ ed as signiﬁ cant determinants of 
25(OH)D concentration,2,8–11,22 and data for these SNPs 
were also available for DIAGRAM and MAGIC.
For the DIAGRAM consortium 
see http://www.diagram-
consortium.org
Figure 1: Study design and mendelian randomisation analysis of SNPs associated with 25(OH)D 
concentrations and risk of type 2 diabetes
Because of some missing genotyping data for each single nucleotide polymorphism (SNP), the sample sizes for 
each study varies; total sample sizes are shown. CCCS=Cambridgeshire case-control study. *Excludes data from 
EPIC-Norfolk already included in EPIC-InterAct.
25(OH)D concentrations
 
 
 
Type 2 diabetes
Ely: 684 non-cases
EPIC-Norfolk: 4765 non-cases 
Total: 5449 non-cases
22 prospective studies
(8492 cases and 89 698 non-cases) 
SNPs associated with 25(OH) D 
(DHCR7 rs12785878,
CYP2R1 rs10741657,
DBP rs4588, and 
CYP24A1  rs17217119)
CCCS: 552 cases and 534 controls
ADDITION-Ely: 896 cases and 1608 controls
Norfolk Diabetes*: 6359 cases and 6785 controls
EPIC-InterAct: 8166 cases and 10 555 non-cases 
DIAGRAM consortium: 12 171 cases and 56 862 controls
Total: 28 144 cases and 76 344 non-cases 
For MAGIC see http://www.
magicinvestigators.org/
downloads/
See Online for appendix
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In EPIC-InterAct, SNPs were assayed by Illumina 660 
quad-chip (Illumina, Little Chesterford, UK; n=9343) at 
the Wellcome Trust Sanger Institute (Hinxton, UK), and 
Metabochip (Illumina; n=9381) at the Department of 
Pathology, University of Cambridge, Cambridge, UK. For 
the other studies (Ely, EPIC-Norfolk, Cambridgeshire, 
ADDITION-Ely, and Norfolk Diabetes), SNPs were 
genotyped with Custom TaqMan SNP Genotyping Assays 
(Applied Biosystems, Paisley, UK) at the Medical 
Research Council Epidemiology Unit, Cambridge, UK. 
The assays used 10 ng of genomic DNA in a 
2·5 μl reaction volume, 384-well plate with a G-Storm 
GS4 Thermal Cycler (GRI, Rayne, UK). Endpoint 
detection and allele calling were done with an ABI 
PRISM 7900HT Sequence Detection System (Applied 
Biosystems, Paisley, UK). All assays passed the quality-
control criteria (call rate greater than 95% and blind 
duplicate concordance of 97% or higher) and the 
frequency of SNPs was in accordance with Hardy–
Weinberg equilibrium (p>0·05 among adults without 
diabetes in each study).
Meta-analysis of 25(OH)D concentration and type 2 
diabetes
We did a random-eﬀ ects meta-analysis of the association 
between 25(OH)D concentrations and type 2 diabetes in 
prospective observational studies, updating a previous 
meta-analysis4 with a search for additional publications 
from Jan 31, 2012, to June 17, 2014 (appendix pp 4, 12–14). 
We only included studies in which participants were of 
European descent for comparability with our mendelian 
randomisation analysis.
Statistical analyses
We assumed each SNP to have an additive eﬀ ect on 
25(OH)D concentration and risk of type 2 diabetes, as 
previously veriﬁ ed.8,10 We ﬁ rst assessed the association of 
each SNP with 25(OH)D concentration using linear 
regression in the control participants of the Ely and EPIC-
Norfolk studies, assuming a linear eﬀ ect of each SNP per 
additional allele on 25(OH)D concentration and an 
additive model across SNPs, with adjustment for age, sex, 
and season of blood draw. We assessed the strength of 
associations using Cragg-Donald F-statistics, with values 
greater than 10 regarded as useful for mendelian 
randomisation analysis.14 Among adults without diabetes 
in prospective and case-control studies, we examined 
whether each SNP as an instrumental variable fulﬁ lled the 
assumption of mendelian randomisation analysis that a 
SNP has no association with potential confounders.14,23
As components of mendelian randomisation analysis 
(ﬁ gure 1), we examined associations of each SNP with 
risk of type 2 diabetes, assuming a linear eﬀ ect of each 
SNP on the logit of disease risk (in logistic models) or 
on the linear predictor of disease risk (in the Cox 
model) per additional variant allele, and an additive 
model across SNPs, with adjustment for age, sex, and 
BMI. We used logistic regression for the case-control 
studies and Prentice-weighted Cox regression for EPIC-
InterAct (case-cohort study).24 We chose to adjust for 
BMI because DIAGRAM included study-speciﬁ c 
estimates after adjustment for BMI18 and because body 
size might account for non-speciﬁ c genetic and 
biological variation of 25(OH)D—eg, by diluting blood 
25(OH)D concentrations.25
For the main mendelian randomisation analysis, we 
used a Bayesian likelihood-based method to estimate the 
unconfounded association of genetically predicted 
concentrations of 25(OH)D with risk of type 2 diabetes.14 
This method quantitatively combined summary 
estimates for SNPs, including DIAGRAM data, rather 
than requiring individual-level data from each study.14 
For each SNP, we ﬁ tted a model using WinBUGS,26 
incorporating both measures of the association 
(β coeﬃ  cients and SEs) between SNP and 25(OH)D 
concentration and measures of the association between 
SNP and risk of type 2 diabetes.
The model assumed a linear relationship between 
25(OH)D concentrations and log odds of type 2 
diabetes, and a bivariate normal distribution for the 
estimates of SNP–25(OH)D association and of SNP–
type 2 diabetes association from each study. A bivariate 
model is assumed to allow for correlation between the 
genetic estimates with 25(OH)D concentration and 
with risk of type 2 diabetes when they are estimated in 
a single study for the same participants. Calculation of 
the unconfounded estimate for a 1 SD lower 25(OH)D 
concentration relies on a linearity assumption that 
extrapolates beyond the genetic data; however, this 
issue aﬀ ects only the size of the estimate and not its 
signiﬁ cance.23 An estimate of the log odds ratio (OR) 
was scaled to be per 1 SD of 25(OH)D concentration 
(25·0 nmol/L), a weighted average of the SDs in 
observational studies included in meta-analysis. 
Additionally, we did separate mendelian randomisation 
analyses using allelic scores for SNPs for 25(OH)D 
synthesis (DHCR7 and CYP2R1) and metabolism (DBP 
and CYP24A1).2,8–12 We also did a sensitivity analysis in 
which we combined two previously reported mendelian 
randomisation-based estimates9,11 (not including the 
EPIC-Potsdam study,10 which is a part of EPIC-
InterAct).
We used a similar approach to estimate the un-
confounded association of 25(OH)D concentrations with 
concentrations of fasting glucose, 2-h glucose, fasting 
insulin, and HbA1c. Measures of the SNP–25(OH)D 
association were the same as those used in the mendelian 
randomisation analysis for risk of type 2 diabetes. 
Measures of the SNP–trait associations were taken from 
MAGIC (appendix p 6), with linear regression used for 
the association analysis; concentration of fasting insulin 
was log-transformed.21
Analyses were done with Stata/SE13.1, unless otherwise 
stated. All statistical tests were two-sided (α=0·05).
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Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
In the studies that contributed data to the mendelian 
randomisation analysis to investigate causal associations 
of 25(OH)D concentration with type 2 diabetes and 
glycaemic traits (appendix p 5), most adults were aged 
50–60 years and proportions of women ranged from 35% 
to 65%. Minor allele frequencies of SNPs were consistent 
across the studies: 0·39–0·41 for CYP2R1 rs10741657, 
0·24–0·29 for DHCR7 rs12785878, 0·28–0·30 for DBP 
rs4588, and 0·21–0·22 for CYP24A1 rs17217119.
All four SNPs were associated with 25(OH)D con-
centrations (ﬁ gure 2A; appendix pp 7–9). Concentrations 
of 25(OH)D per risk allele (lowering 25[OH]D con-
centrations) were lower by 3·22 nmol/L (95% CI 1·79–4·66) 
for CYP2R1 rs10741657, 2·40 nmol/L (1·42–3·38) for 
DHCR7 rs12785878, 5·48 nmol/L (4·00–6·96) for DBP 
rs4588, and 2·62 nmol/L (1·57–3·67) for CYP24A1 
rs17217119. There was no clear evidence for pleiotropic 
eﬀ ects of SNPs since they were not associated with other 
baseline factors such as BMI, blood pressure, or physical 
activity (appendix pp 7–8). The Cragg-Donald F-statistic 
ranged from 19·2 to 113·3 across individual SNPs and 
was 191·4 for a score in which the four SNPs were 
combined (appendix p 10). Each SNP accounted for 
0·4–2·0% of the variation in 25(OH)D concentrations, 
and the four SNPs together accounted for 3·6% of the 
variation (appendix p 10).
The SNPs were not signiﬁ cantly associated with risk of 
type 2 diabetes (ﬁ gure 2B, appendix p 10). Per 
25(OH)D-lowering allele, ORs were 1·03 (95% CI 
0·99–1·06) for CYP2R1 rs10741657, 0·99 (0·94–1·05) for 
DHCR7 rs12785878, 1·00 (0·97–1·03) for DBP rs4588, 
and 0·98 (0·91–1·06) for CYP24A1 rs17217119.
Mendelian randomisation analysis showed no signiﬁ cant 
associations of 25(OH)D with risk of type 2 diabetes risk. 
The summary OR per 1 SD lower 25(OH)D concentration 
was 1·01 (95% CI 0·75–1·36; p=0·94; ﬁ gure 3). Similarly, 
the results were not signiﬁ cant for individual alleles or any 
allelic scores (appendix p 11). In the sensitivity analysis in 
which we combined two previously reported mendelian 
randomisation-based estimates,9,11 the results were 
unchanged: OR per 1 SD lower 25(OH)D concentration 
Figure 2: Associations of SNPs related to vitamin D metabolism with circulating concentrations of 25(OH)D (A) and risk of type 2 diabetes (B)
For analysis of 25-hydroxyvitamin D (25[OH]D), summary estimates were obtained from adults without diabetes from two studies, Ely16 and EPIC-Norfolk.4 For 
analysis of type 2 diabetes, summary estimates were obtained from four case-control studies (Cambridgeshire,15 ADDITION-Ely,19,20 Norfolk Diabetes,15 and 
DIAGRAM18) and one case-cohort study (EPIC-InterAct17). SNPs=single nucleotide polymorphisms.
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CYP2R1 rs10741657
DHCR7 rs12785878
DBP rs4588 
CYP24A1  rs17217119
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5449
5375    
Per-allele change in
25(OH)D concentration, 
nmol/L (95% CI) 
–3·22 (–4·66 to –1·79)
–2·40 (–3·38 to –1·42)
–5·48 (–6·96 to –4·00)
–2·62 (–3·67 to –1·57)
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 23 430/65 939
Per-allele odds ratio 
for type 2 diabetes
(95% CI)
1·03 (0·99–1·06)
0·99 (0·94–1·05)
1·00 (0·97–1·03)
0·98 (0·91–1·06)
Figure 3: Mendelian randomisation and observational estimates for eﬀ ect of a 1 SD reduction in 25(OH)D 
concentration on risk of type 2 diabetes
The mendelian randomisation estimate (odds ratio [OR] with 95% CIs) was determined by instrumental 
variable analysis and the observational estimate (relative risk [RR] with 95% CIs) was determined by 
meta-analysis of prospective observational studies. 1 SD of 25-hydroxyvitamin D (25[OH]D) concentration 
was 25·0 nmol/L.
 0·7 0·8  0·9 1·0 1·1 1·2 1·3 1·4
Mendelian randomisation estimate
(28 144 cases/76 344 controls) 
Observational estimate
(8492 cases/89 698 non-cases)
OR 1·01 (0·75–1·36; p=0·94) 
RR 1·21 (1·16–1·27; p=7·3 × 10¹⁹) 
n Eﬀ ect size (95% CI) p value
All four SNPs (CYP2R1 rs10741657, DHCR7 rs12785878, DBP rs4588, and CYP24A1 rs17217119)
Fasting glucose (mmol/L) 46 186 –0·02 (–0·04 to 0·01) 0·28
2-h glucose (mmol/L) 15 234 0·08 (–0·06 to 0·22) 0·25
Fasting insulin (% diﬀ erence)* 46 186 –1·04 (–3·91 to 1·83) 0·48
HbA1c (%) 46 368 0·01 (–0·04 to 0·05) 0·80
Two SNPs near genes related to 25(OH)D synthesis (CYP2R1 rs10741657 and DHCR7 rs12785878)
Fasting glucose (mmol/L) 46 186 –0·03 (–0·08 to 0·02) 0·21
2-h glucose (mmol/L) 15 234 0·11 (–0·13 to 0·35 0·36
Fasting insulin (% diﬀ erence)* 46 186 –5·44 (–10·64 to –0·24) 0·04
HbA1c (%) 46 368 0·02 (–0·03 to 0·06) 0·48
Two SNPs within or near genes related to 25(OH)D metabolism (DBP rs4588 and CYP24A1 rs17217119)
Fasting glucose (mmol/L) 46 186 –0·01 (–0·04 to 0·03) 0·70
2-h glucose (mmol/L) 15 234 0·07 (–0·11 to 0·24) 0·44
Fasting insulin (% diﬀ erence)* 46 186 1·46 (–2·13 to 5·06) 0·43
HbA1c (%) 46 368 –0·03 (–0·06 to 0·01) 0·11
For single nucleotide polymorphisms (SNPs) and glycaemic traits, summary data from MAGIC21 were used; for SNPs 
and 25-hydroxyvitamin D (25[OH]D) concentrations, data from the Ely16 and EPIC-Norfolk4 studies were used. Sample 
sizes varied between SNPs. 1 SD of 25[OH]D concentration was 25·0 nmol/L. *Eﬀ ect size is presented as a percentage 
diﬀ erence in log-transformed fasting insulin concentration. 
Table: Mendelian randomisation estimates of the association between 1 SD lower 25(OH)D 
concentrations and glycaemic traits
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was 1·04 (95% CI 0·82–1·31) for the four SNPs combined, 
1·16 (0·95–1·41) for the two SNPs related to 25(OH)D 
synthesis, and 0·95 (0·64–1·42) for the two SNPs related to 
25(OH)D metabolism.
In the secondary mendelian randomisation analysis for 
glycaemic traits, we identiﬁ ed no signiﬁ cant causal 
associations for the four SNPs combined or for two SNPs 
related to 25(OH)D metabolism (table). For the two SNPs 
related to 25(OH)D synthesis, we noted a signiﬁ cant 
causal association for one of the four traits (table).
In observational studies, investigators have previously 
identiﬁ ed an inverse association of 25(OH)D 
concentrations with risk of type 2 diabetes. We meta-
analysed data from the 11 studies included in our previous 
meta-analysis4 and 11 newly identiﬁ ed studies (appendix 
pp 12–14). Based on this updated meta-analysis of 
22 studies (8492 cases of type 2 diabetes and 89 698 non-
cases), a 1 SD (25·0 nmol/L) lower 25(OH)D concentration 
was associated with an increased risk of type 2 diabetes 
(relative risk 1·21, 95% CI 1·16–1·27; p=7·3 × 10–¹⁹; ﬁ gures 3, 
4). We noted little evidence of heterogeneity (I²=18%, 
95% CI 0–51; p=0·22) or publication bias (Begg’s test 
p=0·48).
Discussion
Although observational evidence from prospective studies 
suggests an association between low concentrations of 
25(OH)D and an increased risk of incident type 2 
diabetes, the results of our mendelian randomisation 
analysis suggest that genetically predicted low con-
centrations of 25(OH)D were not associated with risk of 
type 2 diabetes. This ﬁ nding suggests that the association 
between 25(OH)D concentration and type 2 diabetes 
might not be causal (panel).
Our ﬁ nding by mendelian randomisation analysis was 
consistent with results from two clinical trials, the 
Women’s Health Initiative6 and RECORD.7 Findings 
from neither trial showed a beneﬁ t for risk of type 2 
diabetes with vitamin D supplementation in doses 
of 800 IU per day (20 μg per day) or less,6,7 although these 
doses are probably too low for the potential eﬀ ect of 
vitamin D to be seen.3 Our ﬁ ndings for glycaemic traits 
were also consistent with ﬁ ndings from clinical trials of 
vitamin D supplements and glycaemic outcomes, 
including glucose tolerance and HbA1c concentration.1,3
Mendelian randomisation analyses for 25(OH)D and 
risk of type 2 diabetes have been done for populations 
from Germany10 and Denmark.11 Investigators of neither 
study produced robust evidence of a causal association 
between 25(OH)D concentration and risk of type 2 
diabetes. The investigators of the German study10 reported 
an OR of 1·10 (95% CI 0·68–1·79; p=0·70) per 25·0 nmol/L 
lower concentration of 25(OH)D (rescaled from the 
original presentation of a 5 nmol/L reduction), based on a 
genetic score derived from SNPs within or near ﬁ ve genes 
related to vitamin D metabolism. Investigators of the 
Danish study11 reported no signiﬁ cant association for each 
of two SNPs near CYP2R1 and two SNPs near DHCR7, 
although use of a combined score of two SNPs near 
DHCR7 provided weak causal evidence (p trend=0·04): 
the hazard ratio of the highest to the lowest genetic scores 
for lowering 25(OH)D concentrations (ie, the greatest to 
least 25[OH]D-lowering eﬀ ect) was 1·11 (95% CI 
0·96–1·29; p=0·17).
In a Norwegian study,9 the investigators reported 
signiﬁ cant associations of 12 SNPs related to vitamin D 
metabolism with 25(OH)D concentration, but not with 
type 2 diabetes.9 Consistent with the null ﬁ ndings for 
any of the individual SNPs, our ﬁ ndings also do not 
support a causal association between 25(OH)D 
concentration and risk of type 2 diabetes, with even 
greater precision than the Norwegian study. Moreover, 
the ﬁ ndings from our mendelian randomisation 
analysis suggest that 25(OH)D concentrations are 
associated with neither increased nor decreased risk of 
type 2 diabetes. This ﬁ nding is supported by the 
results of our mendelian randomisation analysis of 
25(OH)D concentrations and glycaemic traits (to our 
knowledge, the ﬁ rst such analysis that has been 
reported), which showed no causal association.
Our ﬁ ndings challenge some views about the biological 
roles of vitamin D. Although the direct mechanisms are 
unclear, previous ﬁ ndings have suggested roles for 
Figure 4: Meta-analysis of 22 prospective studies for associations of 1 SD lower 25(OH)D concentration with 
risk of type 2 diabetes in populations of European descent
1 SD of 25-hydroxyvitamin D (25[OH]D) concentration was 25·0 nmol/L. *Indicates studies added in this updated 
analysis (references 17–27 in appendix); other studies were included in our previous meta-analysis.4
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vitamin D in type 2 diabetes.1,3 For example, results of 
rodent experiments showed that 1,25-dihydroxyvitamin D 
(1,25[OH]2D), an active form of vitamin D, regulates 
calcium-dependent signalling, modulates insulin 
secretion in pancreatic β cells, and reduces lipotoxicity of 
free fatty acids.3 Notably, concentrations of 25(OH)D and 
1,25(OH)2D are weakly correlated (r<0·3).27 Thus, our 
mendelian randomisation analysis and others10,11 might 
be limited in their ability to elucidate a causal role of 
biologically active vitamin D. This ﬁ nding should 
therefore stimulate future research into 1,25(OH)2D, 
which remains understudied because of its short half-life 
(12–36 h vs 3 weeks for 25[OH]D) and its low 
concentration in blood (less than 1% of the concentration 
of 25[OH]D).27
Cautious interpretation is also necessary because of 
the roles of genes related to vitamin D metabolism. The 
DBP gene encoding vitamin D-binding protein, involved 
in 25(OH)D transport, is an unconfounded determinant 
of 25(OH)D concentration, but might have an opposing 
genetic eﬀ ect on 1,25(OH)2D. The DBP gene product 
associated with increased 25(OH)D concentrations 
might sequester 25(OH)D in blood and reduce 
bioavailability of 25(OH)D. This possibility has been 
supported by evidence from Powe and colleagues,22 who 
reported that DBP alleles that increased blood 
concentrations of 25(OH)D were associated with 
reduced bone mineral density. Therefore, 25(OH)D 
represents vitamin D status, but not necessarily the 
amount of bioavailable vitamin D. Thus, existing 
mendelian randomisation analyses, including ours, 
cannot to accurately predict amounts of bioavailable 
vitamin D. This possibility and the potential of 
mendelian randomisation analysis to be used to 
investigate bioavailable 25(OH)D, as well as circulating 
vitamin D-binding protein and 1,25(OH)2D, need to be 
studied. Moreover, functions independent of diabetes 
aetiology should also be investigated in the future, since 
vitamin D-binding protein might have diverse anti-
inﬂ ammatory functions and results of mendelian 
randomisation analyses have supported a causal 
antihypertensive role of vitamin D.2,28
Our analysis has several strengths. It is the largest 
mendelian randomisation analysis for 25(OH)D 
concentrations and risk of type 2 diabetes, with four 
times as many cases of type 2 diabetes as previous 
research.9–11 Furthermore, it includes a novel mendelian 
randomisation analysis of four glycaemic traits and an 
updated meta-analysis of observational studies assessing 
25(OH)D concentration and risk of type 2 diabetes.
Our study also has limitations. Our mendelian 
randomisation analyses and meta-analysis of 
observational studies combined data from several 
studies to maximise power, which could introduce bias 
due to diﬀ erent study designs that can be diﬃ  cult to 
quantify with respect to the deﬁ nition of endpoints and 
measurement of exposures. Despite no evidence of 
such bias, we cannot rule it out as an explanation for 
the null ﬁ nding. The four SNPs investigated in this 
study account for only 3·6% of the variation in 25(OH)D 
concentration, as previously reported.8,10 This limitation 
could be minimised by examining several SNPs from a 
single gene or from the whole genome as polygenic 
eﬀ ects, although increasing the diversity of the SNP 
panel also brings increased potential for pleiotropic 
eﬀ ects.2,11,29 Another limitation is that the use of total 
25(OH)D concentration cannot distinguish between 
endogenous 25(OH)D3 and exogenous vitamin D, 
including 25(OH)D2. Future research to separate the 
two should improve genetic evidence further. 
Additionally, we assumed linear associations between 
SNPs, 25(OH)D concentrations, and risk of type 2 
diabetes, and did not examine diﬀ erent physiological 
ranges of 25(OH)D concentration. Threshold eﬀ ects of 
genes on 25(OH)D concentration and of 25(OH)D 
concentration on risk of type 2 diabetes could be 
present, for example, depending on amounts of 
Panel: Research in context
Systematic review
We searched PubMed for reports of relevant studies published in any language before 
June 17, 2014, about 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, and 
incident type 2 diabetes, using search terms related to vitamin D concentrations 
(“25-hydroxy vitamin D” or “25(OH)D” or “vitamin D”) and diabetes outcomes 
(“diabetes” or “glucose” or “metabolic syndrome” or “hyperglycaemia”). We also searched 
PubMed for reports of mendelian randomisation studies, published in any language up to 
Aug 4, 2014, for the association of 25(OH)D concentrations and type 2 diabetes, using 
search terms related to mendelian randomisation studies (“mendelian randomisation” or 
“mendelian randomization”), vitamin D concentrations (“25-hydroxy vitamin D” or 
“25(OH)D” or “vitamin D”), and type 2 diabetes outcomes (“type 2 diabetes” or “T2D”). 
We reviewed reference lists of articles identiﬁ ed during the searches. We identiﬁ ed three 
studies9–11 that examined causal associations between 25(OH)D concentrations and risk of 
type 2 diabetes. Although results of observational studies suggested that low circulating 
concentrations of 25(OH)D were associated with an increased risk of type 2 diabetes, our 
search showed that previous evidence for the causal association between 25(OH)D and 
type 2 diabetes was limited by insuﬃ  cient power, too few single-nucleotide 
polymorphisms, or absence of validation for intermediate risk factors for type 2 diabetes 
including glycaemic traits.
Interpretation
We identiﬁ ed a discordance between the observed inverse association and the null 
association estimated from mendelian randomisation analysis with four relevant genetic 
variants as instruments for the association between circulating 25(OH)D concentrations 
and risk of type 2 diabetes. This ﬁ nding suggests that there is no causal link between 
25(OH)D concentration and risk of type 2 diabetes, and that the observed inverse 
association might be subject to residual confounding and reverse causation bias. Our 
mendelian randomisation study was large and generated more precise mendelian 
randomisation estimates than did previous research.9–11 We also identiﬁ ed no causal 
associations between 25(OH)D concentrations and any glycaemic traits investigated, 
conﬁ rming our main ﬁ nding. Together with existing reports of no beneﬁ t of vitamin D 
supplementation for reducing the incidence of type 2 diabetes,6,7 our null results suggest 
that eﬀ orts to increase concentrations of 25(OH)D might not reduce the risk of type 2 
diabetes, as would be expected from observational evidence.
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sunlight exposure and latitudes of residence. Future 
detailed analyses are warranted, including stratiﬁ cation 
by demographic characteristics and a range of 25(OH)D 
concentrations. Finally, because we studied only white 
European populations, our ﬁ ndings might not be 
generalisable to other ethnic groups.
Our ﬁ ndings suggest that interventions to reduce the 
risk of type 2 diabetes by increasing concentrations of 
25(OH)D are not currently justiﬁ ed. Rather, our ﬁ ndings 
emphasise the need for investigation of the discrepancy 
between the observational evidence and the absence of 
causal evidence. Such discrepancy could be accounted for 
by possible residual confounding in observational studies 
that cannot fully control for confounding. For example, 
physical activity might be a strong confounder, because it 
reduces risk of type 2 diabetes but is independently 
related to sunlight exposure and therefore vitamin D 
status. Existing observational studies generally recorded 
self-reported physical activity, which is subject to errors 
and residual confounding. To resolve this issue, research 
in which physical activity is measured objectively—eg, 
with accelerometers—will be needed to minimise 
potential confounding.5
Adiposity might also confound the association 
substantially. Increased adiposity both lowers 25(OH)D 
concentration and increases the risk of type 2 diabetes, 
as the results of previous mendelian randomisation 
studies have shown.11,12 Most observational studies 
adjusted for measures of adiposity, including BMI, but 
this adjustment might also involve measurement error, 
allowing residual confounding. Additionally, the 
discrepancy between ﬁ ndings of observational and 
mendelian randomisation studies suggest reverse 
causality. For example, subclinical diseases such as 
liver disease can lower production of 25(OH)D as well 
as increase the risk of type 2 diabetes.30 Overall, 
underlying bias might account for the discrepancy 
between observational and causal evidence, justifying 
further research into detailed measurements of 
vitamin D exposure, more precise estimates of lifestyle 
factors, and subclinical characteristics. Such research 
will help us to identify causal factors that increase 
25(OH)D concentration and also reduce the risk of 
type 2 diabetes.
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